On August 9, 2018, the SEC filed an emergency action against Aadi Bioscience, Inc., a San Diego, California-based biopharmaceutical company, alleging that it failed to adequately assess the efficacy and safety of its flagship clinical trial.  According to the SEC's complaint filed in the U.S. District Court for the Southern District of California, Aadi Bioscience has failed to adequately assess the safety and efficacy of its flagship clinical trial, the PRECISION 1 trial.  The SEC's complaint alleges that Aadi Bioscience failed to adequately assess the safety and efficacy of nab-sirolimus and letrozole in patients with advanced or recurrent endometrial cancer.  The SEC's complaint, filed in the U.S. District Court, alleges that Aadi Bioscience violated the antifraud provisions of Section 17(a) of the Securities Act of 1933 ("Securities Act") and Section 10(b) of the Securities Exchange Act of 1934 ("Exchange Act") and Rule 10b-5 thereunder.  Without admitting or denying the allegations in the SEC's complaint, Aadi Bioscience has agreed to the entry of a final judgment that permanently enjoins it from violating Section 17(a) of the Securities Act, Section 10(b) of the Exchange Act and Rule 10b-5 thereunder, and to pay a civil penalty in the amount of $13.3 million.  The settlement is subject to court approval.  The SEC's complaint charges Aadi Bioscience with violating Section 17(a) of the Exchange Act, Section 10(b) and Rule 10b-5 thereunder, Sections 206(1) and 206(2) of the Investment Advisers Act of 1940 ("Advisers Act") and Rule 206(2)-8 thereunder, and Sections 206(1), 206(2), and 206(4) of the Investment Advisers Act of 1940.  Without admitting or denying the SEC's allegations, Aadi Bioscience has consented to the entry of a final judgment permanently enjoining it from future violations of Section 17(a)(2) of the Securities Act and Section 10(b) of the Exchange Act, and Rule 10b-5 thereunder. The settlement is subject to Court approval.  The SEC's investigation, which is continuing, is being conducted by Scott Giacobello, Joseph Catanzaro, Sandler Ahu Demir, and Roger Song of the Philadelphia Regional Office.  The SEC appreciates the assistance of the U.S. Attorney's Office for the Southern District of California, the Federal Bureau of Investigation, and the U.S. Secret Service.